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Introduction
Human carboxylesterases are members of the serine esterase superfamily and are responsible for hydrolysis of a wide variety of xenobiotic and endogenous esters.
They metabolize esters, thioesters, carbamates, and amides to yield soluble acids and alcohols or amines (Satoh and Hosokawa, 1998; Satoh et al., 2002) . In the human liver, two major isoforms of carboxylesterase, hCE-1and hCE-2, have been identified (Shibata et al., 1993; Schwer et al., 1997) . hCE-2 is a 60-kD monomeric enzyme with a pI value of approximately 4.9, and shares 48% amino acid sequence identity with hCE-1 (Pindel et al., 1997 , Schwer et al., 1997 , Takai et al., 1997 . The CES2 gene, which encodes hCE-2, is located on chromosome 16q22.1 and consists of 12 exons. Distribution of hCE-2 is relatively limited to several tissues, such as the small intestine, colon, heart, kidney, and liver, while hCE-1 is ubiquitously expressed (Satoh et al., 2002; Xie et al., 2002) .
Although both hCE-1 and hCE-2 show broad substrate specificities, hCE-2 is relatively specific for heroin, cocaine (benzoyl ester), 6-acetylmorphine, procaine, and oxybutynin (Satoh et al., 2002; Pindel et al., 1997; Takai et al., 1997) . In addition, hCE-2 is reported to play a major role in the metabolic activation of the anti-tumor drug irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin:
CPT-11). Irinotecan is a water-soluble derivative of the plant alkaloid camptothecin and widely used for treatment of several types of cancer. Irinotecan is converted to 7-ethyl-10-hydroxycamptothecin (SN-38), a topoisomerase inhibitor, by carboxylesterases (Humerickhouse et al., 2000) and further conjugated by hepatic uridine diphosphate glucuronosyltransferase (UGT) to form the inactive metabolite SN-38 glucuronide (SN-38G) (Iyer et al., 1998) . To a lesser extent, irinotecan is also
acid)-1-piperidino]carbonyloxycamptothecin (APC) and 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin (NPC) by cytochrome P450 3A4 (Santos et al., 2000 , Dodds et al., 1998 . Irinotecan and its metabolites are excreted by the efflux transporters, ABCB1 (P-gp), ABCC2 (cMOAT), and ABCG2
(BCRP), via a hepatobiliary pathway (Mathijssen et al., 2001) . Although irinotecan metabolism is rather complex, hCE-2 is a key enzyme that determines the plasma levels of the active metabolite SN-38.
Hepatic hCE-2 activity toward irinotecan varies 3-fold in microsomes obtained from a panel of human livers (Xu et al., 2002) . The activity loosely correlates with hCE-2 protein levels, but some microsomal samples showed unanticipated deviating activities. This result might be caused by genetic polymorphisms, such as single nucleotide polymorphisms (SNPs) in the CES2 gene. Several SNPs and haplotypes have been reported for the CES2 gene (Charasson et al., 2004 , Marsh et al., 2004 , Wu et al., 2004 , and large ethnic differences in CES2 SNP frequencies are found among 
DNA sequencing
Total genomic DNA was extracted from blood leukocytes or Epstein-Barr virus transformed lymphocytes and used as a template in the polymerase chain reaction (PCR).
Sequence data of the CES2 gene from 72 allergic patients and 81 cancer patients were described previously (Kim et al., 2003) . Additionally, the CES2 gene was sequenced from 13 allergic patients and 96 cancer patients. Amplification and sequencing of the CES2 gene were performed as previously described (Kim et al., 2003) . Rare SNPs found in only one heterozygous subject were confirmed by sequencing PCR fragments produced by amplification with a high fidelity DNA polymerase KOD -Plus-(TOYOBO, Tokyo, Japan). Genbank Accession number NT_010498.15 was used as the reference sequence. Separately, the diplotype configurations (combinations of haplotypes) were inferred by LDSUPPORT software, which determines the posterior probability distribution of the diplotype configuration for each subject based on estimated haplotype frequencies (Kitamura et al., 2002) . The haplotype groups were numbered according to the allele nomenclature systems suggested by Nebert (2000) . The haplotypes harboring nonsynonymous or defective alleles were assigned as haplotype groups *2 to *6. The subgroups were described as the numbers plus small alphabetical letters.
Linkage disequilibrium (LD) and haplotype analyses

Administration of irinotecan and pharmacokinetic analysis
The demographic data and eligibility criteria for 177 cancer patients who received irinotecan in the National Cancer Center Hospitals (Tokyo and Chiba, Japan)
were described elsewhere (Minami et al., 2007) .
Each patient received a 90-min intravenous infusion at doses of 60 to 150 mg/m 2 , which varied depending on regimens/co-administered drugs: i.e., irinotecan dosages were 100 or 150 mg/m 2 for monotherapy and combination with 5-FU, 150 mg/m 2 for combination with mitomycin C (MMC) and 60 (or 70) mg/m 2 for combination with platinum anticancer drugs. Heparinized blood was collected before administration of irinotecan and at 0 min (end of infusion), 20 min, 1 h, 2 h, 4 h, 8 h, and 24 h after infusion. Plasma concentrations of irinotecan, SN-38, and SN-38G were determined as described previously (Sai et al., 2002) . The AUCs from time 0 to infinity of irinotecan and its metabolites were calculated as described (Sai et al., 2004) .
Associations between genotypes and pharmacokinetic parameters including the AUC ratio (SN-38+SN-38G)/CPT-11 were evaluated in 176 patients in which PK parameters were obtained.
Construction of expression plasmids
The coding region of CES2L (long form) cDNA starts at an additional ATG translation initiation codon located 192 nucleotides upstream of the conventional ATG codon (Wu et al., 2003) and encodes a 623-amino acid protein found in the NCBI database (NP_003860.2). The wild-type CES2L cDNA was amplified by PCR from
Human Liver QUICK-Clone cDNA (Clontech, Mountain View, CA) using CES2-specific primers, 5'-CACCCACCTATGACTGCTCA-3' and 5'-AGGGAGCTACAGCTCTGTGT-3'. The PCR was performed with 1 unit of a high fidelity DNA polymerase KOD -Plus-(TOYOBO, Tokyo, Japan) and 0.5 µM of the CES2 specific primers. The PCR conditions were 94°C for 2 min, followed by 35 cycles of 94°C for 30 sec, 60°C for 30 sec, and 68°C for 3 min, and then a final extension at 68°C for 5 min. The PCR products were cloned into the pcDNA3.1 vector by a directional TOPO cloning procedure (Invitrogen, Carlsbad, CA) and the sequences were confirmed in both directions. The resultant plasmid was designated pcDNA3.1/CES2L-WT. The 1A>T variation was introduced into pcDNA3.1/CES2L-WT by using a QuikChange Multi site-directed mutagenesis kit (Stratagene, La Jolla, CA) with the 5'-phosphorylated oligonucleotide, 5'-phospho-GAGACCAGCGAGCCGACCTTGCGGCTGCACAGACTTCG-3' (the substituted nucleotide is underlined). The sequence of the variant cDNA was confirmed in both strands, and the resultant plasmid was designated pcDNA3.1/CES2L-A1T.
Expression plasmids for the short-form wild-type (CES2S) and Arg206His
1 0 variant CES2 were prepared and introduced into COS-1 cells according to the method described previously (Kubo et al., 2005) .
Expression of wild-type and variant CES2 proteins in COS-1 cells
Expression of wild-type and variant CES2 proteins in COS-1 cells was examined as described previously (Kubo et al., 2005) . Briefly, microsomal fractions 
Determination of CES2 mRNA by Real-Time RT-PCR
Total RNA was isolated from transfected COS-1 cells using the RNeasy Mini kit (QIAGEN, Tokyo, Japan). Following RNase-free DNase treatment of samples to minimize plasmid DNA contamination, first-strand cDNA was prepared from 1 µg of total RNA using the High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA) with random primers. Real-time PCR assays were performed with the ABI7500
Real Time PCR System (Applied Biosystems) using the TaqMan Gene Expression
Assay for CES2 (Hs01077945_m1; Applied Biosystems) according to the manufacturer's instructions. The relative mRNA levels were determined using calibration curves obtained from serial dilutions of the pooled wild-type CES2 cDNA.
Samples without reverse transcriptase were routinely included in the RT-PCR reactions to measure possible contributions of contaminating DNA, which was usually less than 1% of the mRNA-derived amplification. Transcripts of ß-actin were quantified as internal controls using TaqMan ß-actin Control Reagent (Applied Biosystems), and normalization of CES2 mRNA levels were based on ß-actin concentrations.
Enzyme assay
CPT-11 hydrolyzing activity of the post-mitochondrial supernatants (microsomal fraction plus cytosol) was assayed over the substrate concentration range of 0.25 -50 µM as described previously (Kubo et al., 2005) , except that the hydrolysis product, SN-38, was determined by the HPLC method of Hanioka et al. (2001) .
Statistical analysis
Statistical analysis of the differences in the AUC ratios among CES2 diplotypes, co-administered drugs or irinotecan dosages was performed using the Kruskal-Wallis 
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Results
CES2 variations detected in a Japanese population
Previously, the promoter region, all 12 exons and their flanking introns of the CES2 gene were sequenced from 72 allergic patients and 81 cancer patients, and resulted in the identification of 12 novel SNPs (Kim et al., 2003) . Additionally, the same region of CES2 was sequenced from 13 allergic patients and 96 cancer patients. A total of 21
SNPs were found in 262 Japanese subjects (Table 1) . Novel SNPs found in this study were -1233T>C, 1A>T, IVS2-71C>G, IVS7+27G>A, and IVS9+78C>T, but their frequency was low (0.002, identified in a single heterozygous subject for each SNP).
The SNP 1A>T is non-synonymous (M1L) and results in a substitution of the translation initiation codon ATG to TTG in the CES2 gene. The other novel SNPs were located in the introns or the 5'-flanking region.
The non-synonymous SNP 424G>A (V142M) reported by our group (Kubo et al., 2005) , and another non-synonymous SNP 617G>A (R206H) published in the dbSNP (rs8192924) and JSNP (ssj0005417) databases were found at a frequency of 0.002.
Recently, several non-coding SNPs in CES2 were also reported (Kim et al., 2003 , Charasson et al., 2004 , Marsh et al., 2004 , Wu et al., 2004 . Among them, the three SNPs, -363C>G in the 5'-UTR, IVS10-108(IVS10+406)G>A in intron 10, and 1749(*69)A>G in the 3'-UTR of exon 12, were found at frequencies of 0.031, 0.269, and 0.239, respectively, in this study. 
Linkage disequilibrium (LD) and haplotype analysis
Therefore, the entire CES2 gene was analyzed as one LD block. The determined/inferred haplotypes are summarized in Fig. 1 , and are shown as numbers plus small alphabetical letters. Our nomenclature of haplotypes is distinct from those of previous studies (Charasson et al., 2004 , Marsh et al., 2004 , Wu et al., 2004 . In this study, the haplotypes without amino acid changes and splicing defects were defined as the *1 group. The haplotypes harboring the nonsynonymous SNPs, 100C>T
(Arg34Trp), 424G>A (Val142Met), 1A>T (Met1Leu), and 617G>A (Arg206His), were assigned as haplotypes *2, *3, *5, and *6, respectively. In addition, the haplotype harboring a SNP at the splice acceptor site of intron 8 (IVS8-2A>G) was assigned as haplotype *4. Several haplotypes were first unambiguously assigned by homozygous variations at all sites (*1a and *1b) or heterozygous variation at only one site (*1d to *1l, *2a, *3a, *4a, and *5a). Separately, the diplotype configurations (combinations of haplotypes) were inferred by LDSUPPORT software. The additionally inferred haplotypes were *1c and *1m to *1o. The most frequent haplotype was *1a (frequency, 0.681), followed by *1b (0.233), *1c (0.027), and *1d (0.017). The frequencies of the other haplotypes were less than 0.01.
Association between CES2 genotypes and irinotecan pharmacokinetics
Next, the relationships between the CES2 genotypes and AUC ratios
[(SN-38+SN-38G)/CPT-11], a parameter of in vivo CES activity (Cecchin et al., 2005) , in irinotecan (CPT-11)-administered patients were investigated. The diplotype distribution of 176 patients, who received irinotecan and were analyzed for the AUC ratio, was similar to that of the 262 subjects. We preliminarily examined the effects of irinotecan dosage and co-medication on the AUC ratio and obtained significant To estimate the effects of nonsynonymous SNPs on the metabolism of irinotecan, the AUC ratios in the patients carrying nonsynonymous SNPs were compared to the median AUC ratio of the *1/*1 patients. Three nonsynonymous SNPs, 100C>T (Arg34Trp, *2), 1A>T (Met1Leu, *5), and 617G>A (Arg206His, *6), and a SNP at the splice acceptor site of intron 8 (IVS8-2A>G, *4) were found in 177 patients who received irinotecan. These SNPs were single heterozygotes. The AUC ratios of the patients with *2a/*1a (0.17) and *5a/*1a (0.10) in the monotherapy group were 60% and 36%, respectively, of the median value for the *1/*1 group (0.28) and substantially lower than the 25 percentile of the *1/*1 group (0.23) (Fig. 2) . It must be noted that the *5a/*1a patient had an extremely low AUC ratio. The AUC ratio of the *6 heterozygote who received cisplatin (0.25) was lower than the median value (0.37) but within the range for the *1/*1 group treated with platinum-containing drugs (Fig. 2) .
To clarify the functional significance of the novel variant Met1Leu (*5), the protein expression level of CES2 carrying the nonsynonymous SNP 1A>T was examined. Wu et al. (2003) reported that transcription of CES2 mRNA was initiated from several transcriptional start sites, resulting in the expression of three CES2 transcripts. Two longer transcripts carry a potential inframe translational initiation codon ATG at -192 that can encode an open reading frame (ORF) extending 64 residues at the amino terminus, as shown in the reference sequence in the NCBI database (NP_003860.2). Therefore, the expression of the CES2 protein from the long CES2 ORF (CES2L), which encodes a potential 623 residue protein, was analyzed. Western analysis of membrane fraction proteins obtained from COS-1 cells transfected with the expression plasmid pcDNA3.1/CES2L-WT showed that the mobility (about 60 kD) of the protein product from the CES2L cDNA was the same as that from the CES2S cDNA, which encodes a 559 residue protein (Kubo et al., 2005) , and the CES2 protein in the human liver microsome (Fig. 3A) . Western blot analysis of whole cell extracts also showed that CES2L yielded a single 60-kD protein product (data not shown), indicating that translation of CES2 was initiated from the second ATG codon of the CES2L ORF, but not from the inframe translation initiation codon located at -192.
When the effect of the 1A>T SNP on the expression of the CES2 protein was examined by Western blotting (Fig. 3A) , the relative expression levels of CES2 protein from cells transfected with plasmid pcDNA3.1/CES2L-A1T were 11.7 ± 2.4 % (p = 0.0003) of the wild-type. The mRNA expression levels determined by the TaqMan real-time RT-PCR assay were similar between the wild-type and variant CES2L cDNAs in COS-1 cells (Fig. 4A) , indicating that the 1A>T SNP affects translational, but not transcriptional, efficiency. Thus, the Met1Leu variant was functionally deficient. (Fig. 3B) . No significant differences in the mRNA expression levels determined by the TaqMan real-time RT-PCR assay were observed between the wild-type and 617G>A variant CES2s (82 ± 7%, p = 0.06) (Fig. 4B) . Table 2 summarizes the apparent kinetic parameters for CPT-11 hydrolysis of wild-type and , 1996) , and mitochondrial acetoacetyl-CoA thiorase (Fukao et al., 2003) . Thus, it is likely that the 1A>T variation is a low-activity variation.
In vitro functional analysis of the
The functional effect of the known nonsynonymous SNP 617G>A (Arg206His) was also investigated. The Arg206 residue is located in the α-helix within the catalytic domain and conserved among human carboxylesterases (Bencharit et al., 2002) .
However, no significant differences were found between the intrinsic enzyme activities of the wild-type and Arg206His variant for irinotecan hydrolysis.
In this study, 20 haplotypes of the CES2 gene were identified. The most frequent haplotype was *1a (frequency, 0. European-Americans (0.063) (Wu et al., 2004) . However, the *1b-tagging SNP 1749A>G (0.239 in this study) was detected only in Asian-Americans with a low frequency (0.03) (Wu et al., 2004) . The frequency of the *1c-tagging SNP, -363C>G, also showed marked ethnic differences between Japanese (0.031) and Europeans (0.12) or Africans (0.33) (our data; Marsh et al., 2004) . These findings indicate the existence of large ethnic difference in haplotype structures among African, European and Japanese populations.
In this study, the relationship between the CES2 genotypes and the (SN-38+SN-38G)/CPT-11 AUC ratios of irinotecan-administered patients was analyzed.
First, the relationship between the genotypes and the AUC ratios among the *1/*1 diplotypes in the patient group with or without co-administered drugs was assessed, and no significant differences in the AUC ratios were observed among the *1/*1 diplotypes in each group (Fig. 2) . Wu et al. (2004) reported that the haplotype harboring SNP -363C>G that was homozygous appeared to have lower mRNA levels than the other haplotype groups. In this study, the haplotype having the SNP -363C>G was assigned
2 0 haplotype *1c. However, no functional differences were found between haplotype *1c and the other *1 group haplotypes. Marsh et al. (2004) reported that IVS10-88C>T was associated with reduced RNA expression in colon tumor tissues. However, this SNP was not found in the present study with Japanese subjects.
The major *1 group haplotypes, *1a, *1b and *1c, account for 94 % of Japanese CES2 haplotypes. The current study revealed no association between the major CES2 genotypes and changes in the AUC ratio, indicating that the variability in AUC ratio could not be interpreted by these haplotypes alone.
In irinotecan-administered patients, three nonsynonymous SNPs, 100C>T
(Arg34Trp, *2), 1A>T (Met1Leu, *5), and 617G>A (Arg206His, *6), and a SNP at the splice acceptor site of intron 8 (IVS8-2A>G, *4) were found as single heterozygotes.
The patients heterozygous for Arg34Trp or Met1Leu showed substantially reduced AUC ratios. These results were consistent with in vitro functional analysis for the nonsynonymous SNPs by Kubo et al. (2005) .
In the case of haplotype *6 harboring the nonsynonymous SNP, 617G>A (Arg206His), the AUC ratio of the patient that received cisplatin was lower than the median value but within the range for the *1/*1 group treated with platinum-containing drugs. The protein expression level of the 206His variant was 76 ± 5%, and the Arg206His substitution itself showed no functional differences in intrinsic enzyme activity by in vitro functional analysis. Thus, the impact of the 617G>A (Arg206His) SNP on irinotecan pharmacokinetics might be small.
On the other hand, the AUC ratio of the patient carrying the haplotype *4 was 
